Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Business Wire•01/10/2026•09:00 ET
0
Key Highlights
- ➤Optune Pax (NVCR) approved in Japan for unresectable locally advanced pancreatic cancer
- ➤PANOVA-3 met its primary endpoint with statistically significant median overall survival improvement
- ➤Optune Pax approved for use with gemcitabine and nab-paclitaxel as first-line treatment
- ➤Optune Pax skin adverse events affected 76.3% of treated participants; 7.7% had Grade ≥3 events
Expert Statements
Makoto Ueno, Director, Department of Gastroenterology, Kanagawa Cancer Center, Yokohama
“The approval of Optune Pax provides a promising new treatment option for locally advanced pancreatic cancer, a disease with an urgent need for effective therapies.”
Makoto Ueno, Director, Department of Gastroenterology, Kanagawa Cancer Center, Yokohama
“In the Phase 3 PANOVA-3 trial for Optune Pax, there was a statistically significant improvement in overall survival and pain progression was delayed, helping to preserve overall quality of life for people with this disease.”
Hidehito Kotani, Senior Vice President, Head of Asia Pacific, Novocure
“The approval of Optune Pax by the Ministry of Health, Labour and Welfare is an important milestone for Novocure in our efforts to improve outcomes for some of the most challenging and aggressive cancers, including advanced pancreatic cancer.”
Hidehito Kotani, Senior Vice President, Head of Asia Pacific, Novocure
“Optune Pax is a fundamentally different treatment for solid tumor cancers and we look forward to bringing this option to healthcare providers and people living with locally advanced pancreatic cancer.”
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax(®) for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.
Get started
Create a free account to read the full story.